Literature DB >> 24405492

Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study.

Satish K Garg1, Ronald L Brazg, Timothy S Bailey, Bruce A Buckingham, Robert H Slover, David C Klonoff, John Shin, John B Welsh, Francine R Kaufman.   

Abstract

BACKGROUND: The ASPIRE in-clinic study established that automatic suspension of insulin with the threshold suspend (TS) feature reduces the duration of induced hypoglycemia. The study's crossover design allowed the effects of antecedent hypoglycemia to be studied. SUBJECTS AND METHODS: The study enrolled 50 subjects who exercised until plasma glucose (YSI glucose and lactate analyzer; YSI, Inc., Yellow Springs, OH) reached ≤85 mg/dL. Hypoglycemia was evaluated after the YSI value reached <70 mg/dL. In TS experiments, insulin was stopped for 2 h once a sensor glucose (SG) value of ≤70 mg/dL was detected; in control experiments, basal insulin delivery continued. Subjects were randomly assigned to Group A (TS in Period 1; control in Period 2) or Group B (control in Period 1; TS in Period 2). Experiments were separated by 3-10 days.
RESULTS: Hypoglycemia was 63.7 min shorter in Period 1 TS experiments (no preceding control experiment) than in Period 2 TS experiments (one or more preceding control experiment(s)) (P<0.01). The number of experiments prior to a successful TS experiment was lower for Period 1 than for Period 2 (0.36 ± 0.64 vs. 1.57 ± 0.84; P<0.001), as was the cumulative duration of antecedent hypoglycemia (16.6 min vs. 204.6 min; P<0.001). The between-groups difference in hypoglycemia duration was not attributable to differences in SG rates of change, the duration of exercise, or area under the curve of <70 mg/dL × min in the 2 days before the successful experiment (all P>0.3).
CONCLUSIONS: The TS feature's ability to mitigate hypoglycemia was decreased by an episode or episodes of prolonged antecedent hypoglycemia, suggesting hypoglycemia begets hypoglycemia. The effect of antecedent hypoglycemia should be taken into consideration in the design of future experiments assessing strategies to reduce hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24405492     DOI: 10.1089/dia.2013.0219

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  5 in total

1.  Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.

Authors:  Steven J Russell; Mallory A Hillard; Courtney Balliro; Kendra L Magyar; Rajendranath Selagamsetty; Manasi Sinha; Kerry Grennan; Debbie Mondesir; Laya Ekhlaspour; Hui Zheng; Edward R Damiano; Firas H El-Khatib
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-03       Impact factor: 32.069

2.  A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm.

Authors:  Laurel H Messer; Cari Berget; Gregory P Forlenza
Journal:  Diabetes Technol Ther       Date:  2019-05-29       Impact factor: 6.118

3.  The Accuracy and Efficacy of the Dexcom G4 Platinum Continuous Glucose Monitoring System.

Authors:  Katherine Nakamura; Andrew Balo
Journal:  J Diabetes Sci Technol       Date:  2015-03-23

Review 4.  Metrics for glycaemic control - from HbA1c to continuous glucose monitoring.

Authors:  Boris P Kovatchev
Journal:  Nat Rev Endocrinol       Date:  2017-03-17       Impact factor: 43.330

5.  Factors associated with nocturnal hypoglycemia in at-risk adolescents and young adults with type 1 diabetes.

Authors:  Darrell M Wilson; Peter M Calhoun; David M Maahs; H Peter Chase; Laurel Messer; Bruce A Buckingham; Tandy Aye; Paula K Clinton; Irene Hramiak; Craig Kollman; Roy W Beck
Journal:  Diabetes Technol Ther       Date:  2015-03-11       Impact factor: 6.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.